Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib plus melphalan in BRCA-deficient advanced solid tumors
NL-OMON37339Phase 1Not yet recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Feb 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of olaparib and melphalan in Nonhematologic neoplasms and breast cancer (2 cohorts), sponsored by Netherlands Cancer Institute. Primary endpoints: Recommended phase II dose and Dose-limiting toxicity. Planned start Feb 2012; status: not yet recruiting.
02
Drugs
olaparibmelphalan
03
Conditions
Nonhematologic neoplasmsbreast cancer
Beyond the preview
Go deeper on NL-OMON37339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37339.